Author - Ziad

CleanFiber seeks approval for expansion project in Hamburg

CleanFiber Buffalo – which won $500,000 in the state-funded business-plan competition in 2016 as UltraCell – is planning to construct a 5,250-square-foot metal panel addition to its existing 60,000-square-foot masonry-and-panel building at 250 Lake Ave., bringing the total size to 66,000 square feet. That will give the company more room for material handling, as well as new equipment, as part of what CEO Jonathan Strimling described as a $15 million investment in the facility. The project will be reviewed at...
Read more...

From the bottom of rocks to the halls of Harvard, this CEO has been looking for a new way to feed fish

After founding alternative feed ingredients biotech firm KnipBio in 2013, Larry Feinberg, a baseball loving, mountain biker, says he has brought the business to the cusp of commercialization. "It all looks like a straight line in the rear view mirror, as you are driving it might be a little windy," Feinberg said, reflecting on his life and career so far. Read more >>
Read more...

Elizabeth Banks and Archer Roose Experience their New Bubbly Rosé In the Metaverse. Sort of.

While seemingly every brand has been racing toward the new technological playground known as the metaverse, Archer Roose - a leading canned wine company - has decided to participate in a different way, by highlighting the confusion behind what the metaverse actually is. And they've done so alongside Chief Creative Officer Elizabeth Banks. Read more >>
Read more...

With VC Funding Down 53%, Wasabi Technologies Defies The Odds — Raising $250 Million

It’s hard for startups to raise money these days. So when a startup raised a quarter of a billion dollars last month, it got my attention. Such odds-defying startups offer valuable lessons for all startup CEOs. This comes to mind in considering the news that Boston-based cloud storage company, Wasabi Technologies, closed a $250 million round of funding last month at a $1.1 billion valuation, according to a company press release. Read more >>
Read more...

Landsdowne Labs Awarded Patent for Button Battery Coating to Reduce Ingestion Injuries

LANDSDOWNE LABS, LLC, has been awarded US patent 11,469,465 B2 for a novel battery coating aimed at preventing small, coin-like “button batteries” from causing bodily injuries when swallowed, the company announced yesterday. Such injuries impact many thousands of individuals each year--the vast majority of them children under age 6, who accidentally swallow batteries used to power consumer devices. “We believe our new battery coating has the potential to reduce serious injuries that impact many thousands of lives,” said Melissa Fensterstock,...
Read more...

Wine not? The stars who have released their own wines…

It started off with celebrity perfumes, now celebrity wines, what’s next? A growing list of celebrities have jumped on the bandwagon and released their own bottles. Wine not? Celebrity-owned wines: Elizabeth Banks. In 2021, the ‘Hunger Games’ actress joined the leading artisanal canned wine company U.S. Archer Roose, founded by Marian Leitner-Waldman, in a bid to democratise fine wine. Read more >>
Read more...

Fairfield startup company works on new technology that deactivates ingested button batteries

Landsdowne Labs is developing ChildLok, a technology that will deactivate the battery once swallowed to prevent burns. The company CEO says at least 3,500 button battery ingestion injuries happen in the U.S. each year. Trista Hamsmith, whose 18-month-old Reese Hamsmith died after swallowing one, says she supports this new technology. Read more >>
Read more...

Companies To Watch: CytoAgents

CytoAgents primarily focuses on developing a single lead drug, coded CTO1681, in multiple indications involving cytokine release syndrome (CRS). Simply stated, CRS is “an overreaction of the immune system, commonly known as cytokine storm.” It has many causes and affects many areas and systems of the body. CTO1681 targets the NF-kB (nuclear factor kappa B) signaling pathway to modulate cytokine production, thus reducing inflammation. CytoAgents has early programs in four areas: oncology (with CAR T-cell therapy), dermatology (atopic dermatitis), neurology...
Read more...